Αποτελέσματα Αναζήτησης
6 Ιαν 2023 · Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new...
- FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
Leqembi is the first amyloid beta-directed antibody to be...
- FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease.
Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease. The drug works by reducing...
FDA approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans, using the Accelerated Approval pathway.
6 Ιουλ 2023 · The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.
24 Ιουλ 2023 · The Food and Drug Administration (FDA) recently granted full approval to a new Alzheimer’s treatment called lecanemab, which has been shown to moderately slow cognitive and functional decline in early-stage cases of the disease.
2 Ιουλ 2024 · The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion.
